No Detail Found!

Peritonitis - Etiology and Treatment Options: A Systematic Review

Author(s)
Sheikh abdul Khaliq Department of Pharmacy Practice and Pharmaceutics, Faculty of Pharmacy, Hamdard University,Karachi,Pakistan
Muhammad idrees Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University,Karachi,Pakistan
Amna Zameer Department of Pharmacology, Faculty of Pharmacy, Hamdard University,Karachi,Pakistan
Abstract
Peritonitis is an infection with a substantial source of morbidity and death. The mortality rate is 10% to 60%. Its etiology may be infection of bacteria, viruses, or fungi. The objective of the current systematic review is to identify the causes of peritonitis and discuss available treatment options. A systematic review was conducted from the literature from January 2012 to December 2022. More than 60 articles were downloaded; after abstracting relevant information from the studies and assessing quality, data was synthesized and presented by PRISMA flow diagram. The most common cause was bacterial infection; followed by fungal and viral infections. Reported organisms were E. coli, Klebsiella spp., Streptococcus spp., M. tuberculosis, C. trachomatis, Pseudomonas spss., C. albicans, C. glabrata, C. krusei, Cryptococcus spp., and Aspergillus spp., and Feline-infectious-corona-virus. Empiric antibiotics therapy covers broad-spectrum antibacterials; antifungal and surgical interventions are treatment options. The acutely ill patient requires combined medical and surgical methods; culture sensitivity is highly advisable to reduce the chances of failure.
Publication Details
Page(s) 66-73
Published Journal: Liaquat National Journal of Primary Care, Volume: 6, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Virus, Bacteria, Fungi, Bacteria, Peritonitis, empiric therapy, culture-sensitivity
References
Kumar D,Garg I,Sarwar AH,Kumar L,Kumar V,Ramrakhia S .2021 .5): e15301. Cureus, 13 : .
Hsieh YP,Chang CC,Wen YK,Chiu PF,Yang YJPDI .2012 .Predictors of peritonitis and the impact of peritonitis on clinical outcomes of continuous ambulatory peritoneal dialysis patients in Taiwan-10 years' experience in a single center. Perit Dial Int, 34(1) : 85-94.
Clements TW,Tolonen M,Ball CG,Kirkpatrick AW .2021 .Secondary peritonitis and intra-abdominal sepsis: an increasingly global disease in search of better systemic therapies. Scand J Surg, 110(2) : 139-49.
Ross JT,Matthay MA,Harris HW .2018 .Secondary peritonitis: principles of diagnosis and intervention. BMJ, 361 : .
Pörner D,Von Vietinghof S,Nattermann J,Strassburg CP,Lutz P. .2021 .Advances in the pharmacological management of bacterial peritonitis. Expert Opin Pharmacother, 22(12) : 1567-78.
Wiest R,Krag A,Gerbes A .2012 .Spontaneous bacterial peritonitis: recent guidelines and beyond. -300779, 61(2) : 297-310.
Vaid U,Kane GC .2017 .. Tuberculous Peritonitis; Chapter, 26 : 433.
Mor P,Dahiya B,Parshad S,Gulati P,Mehta PK .2022 .Recent updates in diagnosis of abdominal tuberculosis with emphasis on nucleic acid amplification tests. Expert Rev Gastroenterol Hepatol, 202106(1) : 8-49.
Tekes G,Thiel HJ .2016 .Feline coronaviruses: pathogenesis of feline infectious peritonitis. Adv Virus Res, 08(1) : 193-218.
Pramod J,Vijayakumar C,Srinivasan K,Maroju NK,Kumar NR,Balasubramaniyan G. .2018 .3): e2275. Cureus, 10 : .
Marciano S,Diaz JM,Dirchwolf M,Gadano A .2019 .Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Hepat Med, 11 : 13-22.
Doklestić S,Bajec D,Djukić R,Bumbaširević V,Detanac A,Detanac S .2014 .Secondary peritonitis-evaluation of 204 cases and literature review. J Med Life, 7(2) : 132-8.
Ballus J,Lopez-Delgado JC,Sabater-Riera J,Perez-Fernandez XL,Betbese A,Roncal JA .2015 .Surgical site infection in critically ill patients with secondary and tertiary peritonitis: epidemiology, microbiology and influence in outcomes. BMC Infect Dis, 15 : 304.
Mishra SP,Tiwary SK,Mishra M,Gupta SK .2014 .An introduction of tertiary peritonitis. J Emerg Trauma Shock, 7(2) : 130883-2700.
.2016 .Sclerosing encapsulating peritonitis. Sultan Qaboos Univ Med J, 16(2) : e142-e51.
Lindsey WT,Olin BR,Hansen RA,Bentley JP,McGraw-Hill Education JP .2020 .Systematic Review and MetaAnalysis. Aparasu RR, 14 : 151.
Moher D,Liberati A,Tetzlaf J,Altman DG .2009 .Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med, 151(4) : 200908180-9.
Alonso-Coello P,Schünemann HJ,Moberg J,BrignardelloPetersen R,Akl EA,Davoli M .2016 .GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. BMJ, 353 : .
Guevara M,Terra C,Nazar A,Solà E,Fernández J,Pavesi M .2012 .Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol, 06(4) : 759-65.
Niu B,Kim B,Limketkai BN,Sun J,Li Z,Woreta T .2018 .Mortality from spontaneous bacterial peritonitis among hospitalized patients in the USA. Dig Dis Sci, 63(5) : 1327-33.
Piano S,Fasolato S,Salinas F,Romano A,Tonon M,Morando F .2016 .The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology, 63(4) : 1299-309.
Thirumalagiri VR,Reddy SR,Chandra H .2017 .Acute peritonitis secondary to hollow viscous perforation: a clinical study. Int Surg J, 4(7) : 2349-2902.
How J,Azar MM,Meyer JP .2015 .Are nectarines to blame? A case report and literature review of spontaneous bacterial peritonitis due to Listeria monocytogenes. Conn Med, 79(1) : 31-6.
Levallois J,Nadeau-Fredette AC,Labbé AC,Laverdiere M,Ouimet D,Vallée M .2011 .Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center. Int J Infect Dis, 09(1) : e41-e3.
Doklestić S,Bajec D,Djukić R,Bumbaširević V,Detanac A,Detanac S .2014 .Secondary peritonitis-evaluation of 204 cases and literature review. J Med Life, 7(2) : 132-8.
Salzer WL .2018 .Peritoneal dialysis-related peritonitis: challenges and solutions. Int J Nephrol Renovasc Dis, 11(1) : 173-86.
Nadeau-Fredette AC,Bargman JM .2013 .Characteristics and outcomes of fungal peritonitis in a modern North American cohort. Perit Dial Int, 35(1) : 78-84.
Lahmer T,Brandl A,Rasch S,Schmid RM,Huber W. .2016 .7): e0158389. PLoS One, 11 : .
Pauwels S,De Moor B,Stas K,Magerman K,Gyssens IC,Van Ranst M .2012 .Coxsackievirus B1 peritonitis in a patient treated with continuous ambulatory peritoneal dialysis: a case report and brief review of the literature. Clin Microbiol Infect, 03985(10) : 0691-E4.
Montravers P,Blot S,Dimopoulos G,Eckmann C,Eggimann P,Guirao X .2016 .Therapeutic management of peritonitis: a comprehensive guide for intensivists. Intensive Care Med, 42(8) : 1234-47.
Gioia F,Gomez-Lopez A,Alvarez ME,de la Pedrosa EGG,Martín-Davila P,Cuenca-Estrella M .2020 .Pharmacokinetics of echinocandins in suspected candida peritonitis: a potential risk for resistance. Int J Infect Dis, 09(1) : 24-8.
Grau S,Luque S,Campillo N,Samso E,Rodriguez U,GarciaBernedo C .2015 .Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother, 70(10) : 2854-61.
Hall RG,Swancutt MA,Meek C,Lef R,Gumbo T. .2013 .Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or threefourths. Antimicrob Agents Chemother, 57(5) : 12-64.
Rhodes A,Evans LE,Alhazzani W,Levy MM,Antonelli M,Ferrer R .2016 .Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. Intensive Care Med, 43(3) : 304-77.
Kalil AC,Johnson DW,Lisco SJ,Sun J .2017 .Early goal-directed therapy for sepsis: a novel solution for discordant survival outcomes in clinical trials. Crit Care Med, 45(4) : 607-14.
Li PKT,Szeto CC,Piraino B,de Arteaga J,Fan S,Figueiredo AE .2016 .ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int, 36(5) : 481-508.
Sorribas M,Jakob MO,Yilmaz B,Li H,Stutz D,Noser Y .2019 .FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol, 06(6) : 1126-40.
Ho PP,Steinman L PP .2016 .Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA, 113(6) : 1600-5.
Gege C,Hambruch E,Hambruch N,Kinzel O,Kremoser C . .Nonsteroidal FXR ligands: current status and clinical applications. , : .
Cho Y,Johnson DW .2014 .Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis, 02(2) : 278-89.
Sahlawi MA,Wilson G,Stallard B,Manera KE,Tong A,Pisoni RL .2020 .Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review. Perit Dial Int, 40(2) : 132-40.
Zheng Q,Zhu R,Yin Z,Xu L,Sun H,Yu H .2022 .Structural basis for the synergistic neutralization of coxsackievirus B1 by a tripleantibody cocktail. Cell Host Microbe, 08(9) : 1279-94.
Fernández J,Piano S,Bartoletti M,Wey EQ .2020 .Management of bacterial and fungal infections in cirrhosis: the MDRO challenge. J Hepatol, 11(Supp 1) : S101-S17.
0

Citations

0

Downloads

124

Views